Immedica acquires the rights for Ravicti® and Ammonaps® outside North America and Japan


Today, through its entity Medical Need Europe AB, Immedica has acquired rights for the products Ammonaps® and Ravicti®, indicated for the treatment of Urea Cycle Disorders (UCD), in all territories outside North America and Japan from Horizon Pharma plc (NASDAQ: HZNP) (Horizon). The deal encompasses all IP and commercial and distribution rights for the two products in the territories. Horizon will retain rights for the products in North America and Japan.

Ammonaps® has been a reference product for many years in patients suffering from UCD. Ravicti® is a new, innovative product indicated for a highly overlapping UCD patient population and with relevant compliance benefits, which are critical in the treatment of these patients.

“We are really happy to contribute in making these important treatments available for this patient group” says Anders Edvell, MD, PhD and CEO of Immedica.

Ravicti® is currently being launched in Europe. The product has been present on the US market for several years.

Immedica will continue to use distribution partners in Europe and the Middle East. In addition, Immedica will make Ravicti® available for other markets in the territories where it has acquired rights.

“These two products will be important assets in our long-term commitment towards niche medicines and specialty care, primarily in Europe and the Middle East,” concludes Anders Edvell

About Urea Cycle Disorders (UCD)

The urea cycle is a process in which waste (ammonia) is removed from the body. When you eat proteins, the body breaks them down into amino acids. Ammonia is produced from leftover amino acids, and it must be removed from the body.

Several inherited conditions can cause problems with this waste-removal process. People with a urea cycle disorder are missing a gene that makes the enzymes needed to break down ammonia in the body. As a group, these disorders occur in 1 in 30,000 newborns in the territories where Immedica has acquired rights.

Typically, symptoms such as confusion, nausea, vomiting, decreased food intake and increased sleepiness occur within the first week after birth.

About Immedica

Immedica is a fast-growing private European niche pharma group. Its legal entities are based in Stockholm, Sweden, and it has pan-European commercial coverage, with the Nordics as its stronghold.

Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, and product distribution.

Today, Immedica manages many of its products via operations at Medical Need Europe AB, a niche/orphan pharma company. Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors. More information is available at or

For more information

Anders Edvell, CEO, Immedica

+46 705 44 61 26